Follow
Alfredo Falcone
Alfredo Falcone
Professore Ordinario Oncologia Medica, Università di Pisa, Italy
Verified email at med.unipi.it
Title
Cited by
Cited by
Year
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
34142016
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ...
The Lancet 381 (9863), 303-312, 2013
30422013
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as …
A Falcone, S Ricci, I Brunetti, E Pfanner, G Allegrini, C Barbara, L Crinò, ...
Journal of clinical oncology 25 (13), 1670-1676, 2007
14932007
Randomized trial of TAS-102 for refractory metastatic colorectal cancer
RJ Mayer, E Van Cutsem, A Falcone, T Yoshino, R Garcia-Carbonero, ...
New England Journal of Medicine 372 (20), 1909-1919, 2015
13852015
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ...
The Lancet 392 (10142), 123-133, 2018
11302018
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular …
C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ...
The Lancet Oncology 16 (13), 1306-1315, 2015
11162015
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ...
New England Journal of Medicine 371 (17), 1609-1618, 2014
11022014
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795-801, 2015
10912015
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
7062009
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
6402017
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity
E Giovannetti, N Funel, GJ Peters, M Del Chiaro, LA Erozenci, E Vasile, ...
Cancer research 70 (11), 4528-4538, 2010
5302010
Primary tumor location as a prognostic factor in metastatic colorectal cancer
F Loupakis, D Yang, L Yau, S Feng, C Cremolini, W Zhang, MKH Maus, ...
Journal of the National Cancer Institute 107 (3), dju427, 2015
5262015
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
J Clin Oncol 27 (16), 2622-2629, 2009
5062009
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the …
J Franko, Q Shi, JP Meyers, TS Maughan, RA Adams, MT Seymour, ...
The Lancet Oncology 17 (12), 1709-1719, 2016
4992016
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised …
C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ...
The lancet oncology 20 (6), 849-861, 2019
4362019
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ...
Journal of clinical oncology 25 (10), 1247-1254, 2007
3792007
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases …
B Nordlinger, E Van Cutsem, P Rougier, CH Köhne, M Ychou, A Sobrero, ...
European journal of cancer 43 (14), 2037-2045, 2007
3652007
Quantitative evidence for early metastatic seeding in colorectal cancer
Z Hu, J Ding, Z Ma, R Sun, JA Seoane, J Scott Shaffer, CJ Suarez, ...
Nature genetics 51 (7), 1113-1122, 2019
3562019
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical …
C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ...
JAMA oncology 5 (3), 343-350, 2019
3452019
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a …
J Tabernero, HJ Lenz, S Siena, A Sobrero, A Falcone, M Ychou, ...
The Lancet Oncology 16 (8), 937-948, 2015
3372015
The system can't perform the operation now. Try again later.
Articles 1–20